Protective effect of a synbiotic against multidrug-resistant Acinetobacter baumannii in a murine infection model

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 5, 2016, Pages 3041-3050

  Asahara, Takashi ^a   Takahashi, Akira ^a   Yuki, Norikatsu ^a   Kaji, Rumi ^a   Takahashi, Takuya ^a   Nomoto, Koji ^a  

^a YAKULT CENTRAL INSTITUTE FOR MICROBIOLOGICAL RESEARCH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; FLUOROURACIL; PROBIOTIC AGENT; SYNBIOTIC AGENT;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTION; ANIMAL; BAGG ALBINO MOUSE; BIFIDOBACTERIUM; DISEASE MODEL; DRUG EFFECTS; ENTEROPATHY; FECES; INTESTINE FLORA; MALE; MICROBIOLOGY; MOUSE; MULTIDRUG RESISTANCE; PATHOGENICITY; PHYSIOLOGY; VIROLOGY;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANIMALS; ANTI-BACTERIAL AGENTS; BIFIDOBACTERIUM; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FECES; FLUOROURACIL; GASTROINTESTINAL MICROBIOME; INTESTINAL DISEASES; MALE; MICE; MICE, INBRED BALB C; PROBIOTICS; SYNBIOTICS;

EID: 84965021017     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02928-15     Document Type: Article

References (56)

1. Ayraud-Thévenot S, Huart C, Mimoz O, Taouqi M, Laland C, Bousseau A, Castel O. 2012. Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure. J Hosp Infect 82:290-292. http://dx.doi.org/10.1016/j.jhin.2012.08.016.
2. Ogutlu A, Guclu E, Karabay O, Utku AC, Tuna N, Yahyaoglu M. 2014. Effects of carbapenem consumption on the prevalence of Acinetobacter infection in intensive care unit patients. Ann Clin Microbiol Antimicrob 13:7. http://dx.doi.org/10.1186/1476-0711-13-7.
3. Peleg AY, Seifert H, Paterson DL. 2008. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev 21:538-582. http://dx.doi.org/10.1128/CMR.00058-07.
4. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. 2007. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51:3471-3484. http://dx.doi.org/10.1128/AAC.01464-06.
5. Towner KJ. 2009. Acinetobacter: an old friend, but a new enemy. J Hosp Infect 73:355-363. http://dx.doi.org/10.1016/j.jhin.2009.03.032.
6. Young LS, Sabel AL, Price CS. 2007. Epidemiologic, clinical, and economic evaluation of an outbreak of clonal multidrug-resistant Acinetobacter baumannii infection in a surgical intensive care unit. Infect Control Hosp Epidemiol 28:1247-1254. http://dx.doi.org/10.1086/521660.
7. Corbella X, Pujol M, Ayats J, Sendra M, Ardanuy C, Domínguez MA, Liñares J, Ariza J, Gudiol F. 1996. Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin Infect Dis 23:329-334. http://dx.doi.org/10.1093/clinids/23.2.329.
8. Reid G, Food Agricultural Organization of the United Nations and the WHO. 2005. The importance of guidelines in the development and application of probiotics. Curr Pharm Des 11:11-16. http://dx.doi.org/10.2174/1381612053382395.
9. Hoppe C, Larsen CN, Fondén R, Svensson U, Ouwehand A, Lahtinen S, Kiwaki M, Nomoto K, Kimura K, Eskesen D, Saxelin M, Kajander K, Reid G, Bruce AW, Nurminen P, Korpela R, Tsuji H, Xiao JZ, Salminen S. 2009. Commercially available human probiotic microorganisms, p 441-532. In Lee YK, Salminen S (ed), Handbook of probiotics and prebiotics, 2nd ed. John Wiley and Sons, Inc, New York, NY.
10. Gibson GR, Beatty ER, Wang X, Cummings JH. 1995. Selective stimulation of Bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 108:975-982. http://dx.doi.org/10.1016/0016-5085(95) 90192-2.
11. Colins MD, Gibson GR. 1999. Probiotics, prebiotics, and synbiotics approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 69:S1052-S1057.
12. National Institutes of Health. 1985. Guide for the care and use of laboratory animals. National Institutes of Health publication no. 85-23. National Institutes of Health, Bethesda, MD.
13. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward ME, Brown S, Amyes SGB, Livermore DM. 2006. Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 27:351-353. http://dx.doi.org/10.1016/j.ijantimicag.2006.01.004.
14. Kano M, Masuoka N, Kaga C, Sugimoto S, Iizuka R, Manabe K, Sone T, Oeda K, Nonaka C, Miyazaki K, Ishikawa F. 2013. Consecutive intake of fermented milk containing Bifidobacterium breve strain Yakult and galacto-oligosaccharides benefits skin condition in healthy adult women. Biosci Microbiota Food Health 32:33-39. http://dx.doi.org/10.12938/bmfh.32.33.
15. Asahara T, Shimizu K, Nomoto K, Hamabata T, Ozawa A, Takeda Y. 2004. Probiotic bifidobacteria protect mice from lethal infection with Shiga toxin-producing Escherichia coli O157:H7. Infect Immun 72:2240-2247. http://dx.doi.org/10.1128/IAI.72.4.2240-2247.2004.
16. Fujimoto J, Tanigawa K, Kudo Y, Makino H, Watanabe K. 2011. Identification and quantification of viable Bifidobacterium breve strain Yakult in human faeces by using strain-specific primers and propidium monoazide. J Appl Microbiol 110:209-217. http://dx.doi.org/10.1111/j.1365-2672.2010.04873.x.
17. Ishikawa F, Takayama H, Matsumoto K, Ito M, Chonan O, Deguchi Y, Kikuchi-Hayakawa H, Watanuki M. 1995. Effects of β1-4 linked galactooligosaccharides on human fecal microflora. Bifidus 9:5-18.
18. Matsuda K, Tsuji H, Asahara T, Kado Y, Nomoto K. 2007. Sensitive quantitative detection of commensal bacteria by rRNA-targeted reverse transcription-PCR. Appl Environ Microbiol 73:32-39. http://dx.doi.org/10.1128/AEM.01224-06.
19. Matsuda K, Tsuji H, Asahara T, Matsumoto K, Takada T, Nomoto K. 2009. Establishment of an analytical system for the human fecal microbiota, based on reverse transcription-quantitative PCR targeting of multicopy rRNA molecules. Appl Environ Microbiol 75:1961-1969. http://dx.doi.org/10.1128/AEM.01843-08.
20. Kikuchi H, Yajima T. 1992. Correlation between water-holding capacity of different types of cellulose in vitro and gastrointestinal retention time in vivo of rats. J Sci Food Agric 60:139-146. http://dx.doi.org/10.1002/jsfa.2740600202.
21. Sugawara G, Nagino M, Nishio H, Ebata T, Takagi K, Asahara T, Nomoto K, Nimura Y. 2006. Perioperative synbiotic treatment to prevent postoperative infectious complications in biliary cancer surgery: a randomized controlled trial. Ann Surg 244:706-714. http://dx.doi.org/10.1097/01.sla.0000219039.20924.88.
22. Takagi K, Nakao M, Ogura Y, Nabeshima T, Kunii A. 1994. Sensitive colorimetric assay of serum diamine oxidase. Clin Chim Acta 226:67-75. http://dx.doi.org/10.1016/0009-8981(94)90103-1.
23. Matsumoto S, Setoyama H, Imaoka A, Okada Y, Amasaki H, Suzuki K, Umesaki Y. 1995. Gamma delta TCR-bearing intraepithelial lymphocytes regulate class II major histocompatibility complex molecule expression on the mouse small intestinal epithelium. Epithelial Cell Biol 4:163-170.
24. Kang YJ, Otsuka M, van den Berg A, Hong L, Huang Z, Wu X, Zhang DW, Vallance BA, Tobias PS, Han J. 2010. Epithelial p38alpha controls immune cell recruitment in the colonic mucosa. PLoS Pathog 6:e1000934. http://dx.doi.org/10.1371/journal.ppat.1000934.
25. Roxas JL, Koutsouris A, Bellmeyer A, Tesfay S, Royan S, Falzari K, Harris A, Cheng H, Rhee KJ, Hecht G. 2010. Enterohemorrhagic E. coli alters murine intestinal epithelial tight junction protein expression and barrier function in a Shiga toxin independent manner. Lab Invest 90: 1152-1168. http://dx.doi.org/10.1038/labinvest.2010.91.
26. Song HL, Lv S, Liu P. 2009. The roles of tumor necrosis factor-alpha in colon tight junction protein expression and intestinal mucosa structure in a mouse model of acute liver failure. BMC Gastroenterol 9:70. http://dx.doi.org/10.1186/1471-230X-9-70.
27. Agustí C, Pujol M, Argerich MJ, Ayats J, Badía M, Domínguez MA, Corbella X, Ariza J. 2002. Short-term effect of the application of selective decontamination of the digestive tract on different body site reservoir ICU patients colonized by multi-resistant Acinetobacter baumannii. J Antimicrob Chemother 49:205-208. http://dx.doi.org/10.1093/jac/49.1.205.
28. Timsit JF, Garrait V, Misset B, Goldstein FW, Renaud B, Carlet J. 1993. The digestive tract is a major site for Acinetobacter baumannii colonization in intensive care unit patients. J Infect Dis 168:1336-1337. http://dx.doi.org/10.1093/infdis/168.5.1336.
29. Pachón-Ibáññez ME, Docobo-Pérez F, López-Rojas R, Domínguez-Herrera J, Jiménez-Mejias ME, García-Curiel A, Pichardo C, Jiménez L, Pachón J. 2010. Efficacy of rifampin and its combinations with imipenem, sulbactam, and colistin in experimental models of infection caused by imipenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 54:1165-1172. http://dx.doi.org/10.1128/AAC.00367-09.
30. Yamada K, Yanagihara K, Kaku N, Harada Y, Migiyama Y, Nagaoka K, Morinaga Y, Nakamura S, Imamura Y, Miyazaki T, Izumikawa K, Kakeya H, Hasegawa H, Mikamo H, Kohno S. 2013. Azithromycin attenuates lung inflammation in a mouse model of ventilatorassociated pneumonia by multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 57:3883-3888. http://dx.doi.org/10.1128/AAC.00457-13.
31. Thompson MG, Black CC, Pavlicek RL, Honnold CL, Wise MC, Alamneh YA, Moon JK, Kessler JL, Si Y, Williams R, Yildirim S, Kirkup BC, Jr, Green RK, Hall ER, Palys TJ, Zurawski DV. 2014. Validation of a novel murine wound model of Acinetobacter baumannii infection. Antimicrob Agents Chemother 58:1332-1342. http://dx.doi.org/10.1128/AAC.01944-13.
32. Zhang Y, Zhu Y, Gupta A, Huang Y, Murray CK, Vrahas MS, Sherwood ME, Baer DG, Hamblin MR, Dai T. 2014. Antimicrobial blue light therapy for multidrug-resistant Acinetobacter baumannii infection in a mouse burn model: implications for prophylaxis and treatment of combat-related wound infections. J Infect Dis 209:1963-1971. http://dx.doi.org/10.1093/infdis/jit842.
33. López-Rojas R, McConnell MJ, Jiménez-Mejías ME, Domínguez-Herrera J, Fernández-Cuenca F, Pachón J. 2013. Colistin resistance in a clinical Acinetobacter baumannii strain appearing after colistin treatment: effect on virulence and bacterial fitness. Antimicrob Agents Chemother 57:4587-4589. http://dx.doi.org/10.1128/AAC.00543-13.
34. Luo G, Spellberg B, Gebremariam T, Bolaris M, Lee H, Fu Y, French SW, Ibrahim AS. 2012. Diabetic murine models for Acinetobacter baumannii infection. J Antimicrob Chemother 67:1439-1445. http://dx.doi.org/10.1093/jac/dks050.
35. Talreja D, Kaye KS, Yu FS, Walia SK, Kumar A. 2014. Pathogenicity of ocular isolates of Acinetobacter baumannii in a mouse model of bacterial endophthalmitis. Invest Ophthalmol Vis Sci 55:2392-2402. http://dx.doi.org/10.1167/iovs.13-13401.
36. Tanaka A, Sadahiro S, Suzuki T, Okada K, Saito G. 2014. Randomized controlled trial comparing subcuticular absorbable suture with conventional interrupted suture for wound closure at elective operation of colon cancer. Surgery 155:486-492. http://dx.doi.org/10.1016/j.surg.2013.10.016.
37. Brook I. 2016. Spectrum and treatment of anaerobic infections. J Infect Chemother 22:1-13. http://dx.doi.org/10.1016/j.jiac.2015.10.010.
38. Kanamori Y, Hashizume K, Kitano Y, Tanaka Y, Morotomi M, Yuki N, Tanaka R. 2003. Anaerobic dominant flora was reconstructed by synbiotics in an infant with MRSA enteritis. Pediatr Int 45:359-362. http://dx.doi.org/10.1046/j.1442-200X.2003.01728.x.
39. Kanazawa H, Nagino M, Kamiya S, Komatsu S, Mayumi T, Takagi K, Asahara T, Nomoto K, Tanaka R, Nimura Y. 2005. Synbiotics reduce postoperative infectious complications: a randomized controlled trial in biliary cancer patients undergoing hepatectomy. Langenbecks Arch Surg 390:104-113. http://dx.doi.org/10.1007/s00423-004-0536-1.
40. Shimizu K, Ogura H, Goto M, Asahara T, Nomoto K, Morotomi M, Matsushima A, Tasaki O, Fujita K, Hosotsubo H, Kuwagata Y, Tanaka H, Shimazu T, Sugimoto H. 2009. Synbiotics decrease the incidence of septic complications in patients with severe SIRS: a preliminary report. Dig Dis Sci 54:1071-1078. http://dx.doi.org/10.1007/s10620-008-0460-2.
41. Ostling CE, Lindgren SE. 1993. Inhibition of enterobacteria and Listeria growth by lactic, acetic and formic acids. J Appl Bacteriol 75:18-24.
42. Eklund T. 1983. The antimicrobial effect of dissociated and undissociated sorbic acid at different pH levels. J Appl Bacteriol 54:383-389. http://dx.doi.org/10.1111/j.1365-2672.1983.tb02632.x.
43. Brocklehurst TF, Lund BM. 1990. The influence of pH, temperature and organic acids on the initiation of growth of Yersinia enterocolitica. J Appl Bacteriol 69:390-397. http://dx.doi.org/10.1111/j.1365-2672.1990.tb01529.x.
44. Erridge C, Moncayo-Nieto OL, Morgan R, Young M, Poxton IR. 2007. Acinetobacter baumannii lipopolysaccharides are potent stimulators of human monocyte activation via Toll-like receptor 4 signalling. J Med Microbiol 56:165-171. http://dx.doi.org/10.1099/jmm.0.46823-0.
45. Matsuda N, Hattori Y. 2006. Systemic inflammatory response syndrome (SIRS): molecular pathophysiology and gene therapy. J Pharmacol Sci 101:189-198. http://dx.doi.org/10.1254/jphs.CRJ06010X.
46. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL, Suzuki T, Taylor TD, Itoh K, Kikuchi J, Morita H, Hattori M, Ohno H. 2011. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469: 543-547. http://dx.doi.org/10.1038/nature09646.
47. Miyauchi E, O'Callaghan J, Buttó LF, Hurley G, Melgar S, Tanabe S, Shanahan F, Nally K, O'Toole PW. 2012. Mechanism of protection of transepithelial barrier function by Lactobacillus salivarius: strain dependence and attenuation by bacteriocin production. Am J Physiol Gastrointest Liver Physiol 303:G1029-G1041. http://dx.doi.org/10.1152/ajpgi.00003.2012.
48. Hsieh CY, Osaka T, Moriyama E, Date Y, Kikuchi J, Tsuneda S. 2015. Strengthening of the intestinal epithelial tight junction by Bifidobacterium bifidum. Physiol Rep 3:e12327. http://dx.doi.org/10.14814/phy2.12327.
49. Mariadason JM, Barkla DH, Gibson PR. 1997. Effect of short-chain fatty acids on paracellular permeability in Caco-2 intestinal epithelium model. Am J Physiol 272:G705-G712.
50. Suzuki T, Yoshida S, Hara H. 2008. Physiological concentrations of short-chain fatty acids immediately suppress colonic epithelial permeability. Br J Nutr 100:297-305.
51. Tanaka K, Yano M, Motoori M, Kishi K, Miyashiro I, Ohue M, Ohigashi H, Asahara T, Nomoto K, Ishikawa O. 2012. Impact of perioperative administration of synbiotics in patients with esophageal cancer undergoing esophagectomy: a prospective randomized controlled trial. Surgery 152:832-842. http://dx.doi.org/10.1016/j.surg.2012.02.021.
52. Yokoyama Y, Nishigaki E, Abe T, Fukaya M, Asahara T, Nomoto K, Nagino M. 2014. Randomized clinical trial of the effect of perioperative synbiotics versus no synbiotics on bacterial translocation after oesophagectomy. Br J Surg 101:189-199. http://dx.doi.org/10.1002/bjs.9385.
53. Usami M, Miyoshi M, Kanbara Y, Aoyama M, Sakaki H, Shuno K, Hirata K, Takahashi M, Ueno K, Tabata S, Asahara T, Nomoto K. 2011. Effects of perioperative synbiotic treatment on infectious complications, intestinal integrity, and fecal flora and organic acids in hepatic surgery with or without cirrhosis. J Parenter Enteral Nutr 35:317-328. http://dx.doi.org/10.1177/0148607110379813.
54. Komatsu S, Sakamoto E, Norimizu S, Shingu Y, Asahara T, Nomoto K, Nagino M. 2016. Efficacy of perioperative synbiotics treatment for the prevention of surgical site infection after laparoscopic colorectal surgery: a randomized controlled trial. Surg Today 46:479-490. http://dx.doi.org/10.1007/s00595-015-1178-3.
55. Motoori M, Yano M, Miyata H, Sugimura K, Saito T, Omori T, Fujiwara Y, Miyoshi N, Akita H, Gotoh K, Takahashi H, Kobayashi S, Noura S, Ohue M, Asahara T, Nomoto K, Ishikawa O, Sakon M. 25 November 2015. Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Clin Nutr. http://dx.doi.org/10.1016/j.clnu.2015.11.008.
56. Hayakawa M, Asahara T, Ishitani T, Okamura A, Nomoto K, Gando S. 2012. Synbiotic therapy reduces the pathological gram-negative rods caused by an increased acetic acid concentration in the gut. Dig Dis Sci 57:2642-2649. http://dx.doi.org/10.1007/s10620-012-2201-9.